RCMI Coordinating Center (RCMI CC) Header Logo

Edna M. Mora Piñero

Concepts (73)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Cell-Derived Microparticles
1
2015
8
0.480
Why?
Biological Specimen Banks
1
2015
28
0.470
Why?
Exosomes
1
2015
126
0.410
Why?
Ascorbic Acid
5
2005
74
0.250
Why?
RNA, Small Interfering
4
2012
436
0.230
Why?
Ovarian Neoplasms
3
2015
415
0.210
Why?
Chitosan
2
2011
53
0.160
Why?
Drug Delivery Systems
3
2011
277
0.160
Why?
Gene Silencing
3
2011
154
0.120
Why?
Receptor, EphB4
1
2015
3
0.120
Why?
Antioxidants
3
2005
443
0.120
Why?
Erythropoietin
1
2015
38
0.120
Why?
Neoplasms
5
2011
1377
0.120
Why?
Nanoparticles
2
2011
460
0.110
Why?
Breast Neoplasms
3
2015
1723
0.110
Why?
Neoplasms, Glandular and Epithelial
1
2012
57
0.090
Why?
Mice, Nude
4
2015
408
0.080
Why?
Lipoproteins, HDL
1
2011
48
0.080
Why?
Hydrogels
1
2011
59
0.080
Why?
Cell Cycle Proteins
1
2012
241
0.080
Why?
Melanoma
1
2011
110
0.080
Why?
Oligopeptides
1
2010
109
0.080
Why?
Gene Expression Regulation, Neoplastic
1
2015
968
0.080
Why?
Animals
6
2015
16992
0.070
Why?
Antineoplastic Agents
4
2011
1019
0.060
Why?
Cell Line, Tumor
4
2015
2676
0.060
Why?
Humans
11
2015
43102
0.050
Why?
Orthomolecular Therapy
1
2002
3
0.050
Why?
Copper Sulfate
1
2002
5
0.050
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2015
652
0.040
Why?
Blotting, Western
2
2015
883
0.040
Why?
Mice
4
2012
6644
0.040
Why?
Xenograft Model Antitumor Assays
2
2011
347
0.040
Why?
Female
6
2015
24698
0.030
Why?
Receptors, Erythropoietin
1
2015
6
0.030
Why?
STAT3 Transcription Factor
1
2015
102
0.030
Why?
Infusions, Intravenous
2
2005
53
0.030
Why?
Recombinant Proteins
1
2015
518
0.030
Why?
Injections, Intravenous
2
2004
67
0.020
Why?
Disease Progression
1
2015
667
0.020
Why?
Protein Binding
1
2015
1082
0.020
Why?
Vascular Endothelial Growth Factor A
1
2012
183
0.020
Why?
HCT116 Cells
1
2011
40
0.020
Why?
Neoplasm Invasiveness
1
2012
290
0.020
Why?
Dose-Response Relationship, Drug
2
2005
1124
0.020
Why?
Microspheres
1
2011
49
0.020
Why?
Mice, Inbred C57BL
1
2015
1869
0.020
Why?
Neoplasm Metastasis
1
2011
237
0.020
Why?
Receptors, Cell Surface
1
2010
146
0.020
Why?
Aged, 80 and over
1
2015
2853
0.020
Why?
Neoplasm Proteins
1
2010
228
0.020
Why?
Aged
2
2015
8214
0.020
Why?
RNA, Messenger
1
2012
1271
0.020
Why?
Models, Biological
1
2011
712
0.020
Why?
Middle Aged
2
2015
12222
0.010
Why?
Cell Proliferation
1
2011
1455
0.010
Why?
Palliative Care
1
2005
61
0.010
Why?
Combined Modality Therapy
1
2005
173
0.010
Why?
Young Adult
1
2015
5080
0.010
Why?
Clinical Protocols
1
2003
36
0.010
Why?
Virus Diseases
1
2003
27
0.010
Why?
Bacterial Infections
1
2003
45
0.010
Why?
Clinical Trials as Topic
1
2005
259
0.010
Why?
Anti-Infective Agents
1
2003
75
0.010
Why?
Neoplastic Stem Cells
1
2003
99
0.010
Why?
Drug Resistance, Neoplasm
1
2005
307
0.010
Why?
Pain
1
2005
290
0.010
Why?
Drug Screening Assays, Antitumor
1
2002
157
0.010
Why?
Cell Division
1
2002
311
0.010
Why?
Tumor Cells, Cultured
1
2002
508
0.010
Why?
Treatment Outcome
1
2004
1604
0.010
Why?
Adult
1
2015
13872
0.010
Why?
Male
1
2004
23409
0.000
Why?
Mora Piñero's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (73)
Explore
_
Co-Authors (4)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support